With the presidential debate on the horizon, analysts are speculating how the healthcare industry could be impacted by either candidate.
Hedge fund billionaire Dan Loeb owns a greater than 17% stake in the newly public developer of a drugs including those for treatment of psoriasis.
Relief over the Federal Reserve's slow-and-steady rates plans fueled another day of gains on Thursday.
Stocks in the health care sector are vulnerable to declines following the 2016 presidential election, according to S&P analyst Scott Kessler.
This drug stock has stumbled on a failed clinical trial, but here's why the stock is a bargain right now.
Clovis Oncology shares were higher Wednesday after analysts with Credit Suisse boosted the stock's rating to OUTPERFORM from NEUTRAL.
Brace for extreme turbulence as Mylan's chief executive testifies before Congress and faces further public condemnation.
The executive will testify before the House Committee on Oversight and Government Reform Wednesday.